BiLiJi Biotechnology

Biliji Biotechnology is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of innovative gene therapies. The company focuses on utilizing Adeno-Associated Virus (AAV) vectors to deliver therapeutic genes for the treatment of chronic diseases, with a primary emphasis on ophthalmology. Its lead program, BLJ-001, is an AAV-based gene therapy targeting wet age-related macular degeneration (nAMD) designed to provide a long-lasting alternative to frequent intravitreal injections. Biliji leverages a proprietary platform for vector optimization and manufacturing, aiming to deliver "one-and-done" curative treatments. The company is backed by prominent life science investors, including Qiming Venture Partners and Lilly Asia Ventures, and maintains its own GMP-compliant manufacturing facilities.